Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma

ABSTRACT Introduction Atezolizumab plus bevacizumab (Atez/Bev) has become the standard first‐line therapy for advanced hepatocellular carcinoma (HCC), but optimal second‐line strategies remain unclear. This multicenter retrospective study compared survival outcomes and tumor control among first‐line...

Повний опис

Бібліографічні деталі

Автори:	Masanori Inoue, Sadahisa Ogasawara, Kazuhisa Asahara, Rui Sato, Shunji Watanabe, Haruka Anzai, Kazuo Tsubura, Taro Watabe, Makoto Fujiya, Teppei Akatsuka, Ryo Izai, Keiichi Katayama, Midori Sawada, Takahiro Tsuchiya, Chihiro Miwa, Ryohei Yoshino, Takuya Yonemoto, Kentaro Fujimoto, Hidemi Unozawa, Sae Yumita, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masato Nakamura, Naoya Kanogawa, Shingo Nakamoto, Masayuki Yokoyama, Jun Kato, Michihisa Moriguchi, Takeshi Aramaki, Naoki Morimoto
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Wiley 2026-02-01
Серія:	Cancer Medicine
Предмети:	atezolizumab bevacizumab duration of disease control duration of response hepatocellular carcinoma second line
Онлайн доступ:	https://doi.org/10.1002/cam4.71655
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!